Group 1: Market Performance - Johnson & Johnson (JNJ) and Albertsons Companies (ACI) stocks have provided a hedge against market volatility, with both stocks up 6% year to date [1] - The S&P 500 and Nasdaq are near correction territory, highlighting the defensive nature of JNJ and ACI [1] Group 2: Johnson & Johnson Q1 Results - JNJ's Q1 sales rose 2% to 21.89billion,exceedingestimatesof21.61 billion, driven by DARZALEX, which saw a 20% growth [2] - Q1 earnings increased 2% to 2.77pershare,surpassingEPSexpectationsof2.57 by 7.78% [3] - JNJ has maintained an average earnings surprise of 5.71% over the last four quarters [3] Group 3: Albertsons Q4 Results - Albertsons' Q4 sales increased 2% to 18.79billion,surpassingestimatesof18.62 billion, with E-commerce sales spiking 24% [4] - Q4 EPS of 0.46beatexpectationsof0.40, although it fell from 0.54inthecomparativequarter[5]−AlbertsonshasachievedorexceededtheZacksEPSConsensusineachofthelastfourquarterswithanaverageearningssurpriseof7.2191 billion-91.8billion,abovetheZacksConsensusof89.99 billion, with projected sales growth of 4% in FY26 [8] - JNJ lowered its FY25 EPS guidance to a range of 10.50−10.70, aligning with estimates of 10.51,indicating52.03-2.16,belowexpectationsof2.33, but FY27 EPS is projected to rebound to 2.44[11]−Albertsons′salesareexpectedtoincrease383.25 billion [11] Group 5: Overall Assessment - Both JNJ and ACI currently hold a Zacks Rank 3 (Hold), indicating defensive safety due to the essential nature of their businesses, though there may be better buying opportunities given their guidance [12]